Diagnostic tests and prognostic indicators

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. Ayuk F et al. Ann Hematol. 2015 Jul 24. [Epub ahead of print]. 18F-FDG and 18F-NaF PET/CT Findings of a Multiple Myeloma Patient With Thyroid Cartilage Involvement. Oral A et al. Clin Nucl Med. 2015 Jul 22. [Epub ahead of print]. Tumor associated macrophages (TAMs) and extraczellular…

Related conditions

Neoplastic and Non-Neoplastic Complications of Solid Organ Transplantation in Patients with Preexisting Monoclonal Gammopathy of Undetermined Significance (MGUS). Goebel TE et al. Clin Transplant. 2015 Jul 21. doi: 10.1111/ctr.12595. [Epub ahead of print]. Kidney involvement in Crow-Fukase syndrome. Zouaghi K et al. Saudi J Kidney Dis Transpl. 2015 Jul-Aug;26(4):751-6. doi: 10.4103/1319-2442.160201. Bortezomib produces high hematological response rates with prolonged renal survival…

Emerging treatments

T-cell receptor therapy shows promise in multiple myeloma. Bagcchi S. Lancet Oncol. 2015 Jul 23. pii: S1470-2045(15)00191-6. doi: 10.1016/S1470-2045(15)00191-6. [Epub ahead of print]. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Rapoport AP et al. Nat Med. 2015 Jul 20. doi: 10.1038/nm.3910. [Epub ahead of print]. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple…

Biology and genetics

Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. Mitchell JS et al. Sci Rep. 2015 Jul 24;5:12473. doi: 10.1038/srep12473. MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis. Lazareth A et al. Haematologica. 2015 Jul 23. pii: haematol.2015.127001. [Epub ahead of print]. Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of…

Supportive care

Daily postdilutional hemodiafiltration with FX800 polysulfone dialyzers for removing kappa light chains inmultiple myeloma-induced kidney injury. Tillmann FP. Indian J Nephrol. 2015 Jul-Aug;25(4):237-41. doi: 10.4103/0971-4065.158176. Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients withMultiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. Satlin MJ et al. Biol Blood Marrow Transplant. 2015 Jul 3. pii: S1083-8791(15)00441-3. doi:…

General

Time to redefine Myeloma. Pratt G et al. Br J Haematol. 2015 Jul 27. doi: 10.1111/bjh.13620. [Epub ahead of print]. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Majithia N et al. Am J Hematol. 2015 Jul 27. doi: 10.1002/ajh.24131. [Epub ahead of print]. Limiting early mortality: Do’s and don’ts in the management of patients with newly diagnosed multiple myeloma. Gonsalves…

Complications of myeloma and its treatments

Optimizing the management of patients with spinal myeloma disease. Molloy S et al. Br J Haematol. 2015 Jul 17. doi: 10.1111/bjh.13577. [Epub ahead of print]. Measuring therapy-induced peripheral neuropathy: preliminary development and validation of the Treatment-induced Neuropathy Assessment Scale (TNAS). Mendoza TR et al. J Pain. 2015 Jul 22. pii: S1526-5900(15)00763-4. doi: 10.1016/j.jpain.2015.07.002. [Epub ahead of print]. High-dose therapy improves the bone remodelling…

Current treatments

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. Ludwig H et al. Br J Haematol. 2015 Jul 7. doi: 10.1111/bjh.13582. [Epub ahead of print]. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Voorhees PM et al. Br…